Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Location: United States, California, San Diego
Employees: 51-200
Founded date: 2007
Investors 2
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| 12.07.2023 | Johns Hopk... | ventures.j... |
Mentions in press and media 25
| Date | Title | Description |
| 05.03.2024 | Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | - |
| 28.02.2023 | Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates | /EIN News/ -- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from Single-dose Cohorts Showed Ob... |
| 06.01.2023 | Fate Stock Sinks. Analysts Downgrade Shares on End to Janssen Collaboration and Layoffs. | Fate Therapeutics was sinking Friday as analysts downgraded shares of the stem-cell company after it ended a collaboration agreement with Janssen Biotech and said it was reducing its work force. Fate (ticker: FATE) said in a press release t... |
| 05.01.2023 | Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives | /EIN News/ -- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing Second-generation CD19-targeted CAR NK ... |
| 05.01.2023 | Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen | SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to treat autoimmune diseases and cancer, is now planning to cut back on both jobs and experimental drugs after an early end to a deal with Janss... |
| 22.08.2021 | Anti-aging research foundation sacks CSO Aubrey de Grey for disrupting sexual harassment probe | Caught in the center of a boiling controversy over accusations of sexual harassment leveled against their chief scientific officer, Aubrey de Grey, the board of directors of the SENS Research Foundation moved to fire ... |
| 20.08.2021 | Insilico finds a new partner for AI drug discovery; EU launches Illumina probe after Grail merger close | MIT star researcher and CRISPR pioneer Feng Zhang put a new paper out Thursday in Science detailing how a new technology could alter a field that’s already proven game-changing throughout the Covid-19 pandemic. Zhang and his team have devel... |
| 19.08.2021 | Fate's closely watched stem cell-derived NK program raises red flag over durability of response | At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for ways to craft next-gen cell therapies without relying on patients’ own cells. An early peek at the company’s clinical data looks ... |
| 26.03.2021 | Merck keeps it in the family as Robert Davis hands the CFO keys to Caroline Litchfield; Gilead loses Diana Brainard, with virology exec becoming CEO of AlloVir | Caroline Litchfield → With Robert Davis preparing to take over as Merck’s CEO, the Big Pharma stayed in-house to choose a successor in the job he won’t hold for much longer. Caroline Litchfield, who’s served at Merck since 1990 ... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | Late last summer, one of the earliest stem cell therapy companies got two government decisions in the span of three weeks: The USPTO granted them a patent for iPSC-derived CAR-T cells, and then the FDA cleared them for their first-in-human ... |
Show more